5-Amino-1MQ Side Effects: What the Evidence Actually Shows

REVIEWED BY

Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor

Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.

5-Amino-1MQ side effects — what the evidence actually shows

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

5-Amino-1MQ side effects have never been measured in a human being — not in a trial, not in a case report, not once. Everything published about this NNMT inhibitor comes from mice on high-fat diets and cells in culture. That leaves this page in the same honest bind as our other no-human-data compounds: most “5-Amino-1MQ side effects” articles quietly fill the vacuum with reassurances the science never earned. We won’t. Here is exactly what the four preclinical studies measured, and why “no adverse effects” in a mouse abstract is not a clean bill of health for a person.

Quick Answer: What the 5-Amino-1MQ Side-Effect Data Actually Shows

There is no published human safety data for 5-Amino-1MQ. No clinical trial, no adverse-event table, no case series — the entire literature is four preclinical papers in diet-induced obese mice and cultured adipocytes (PMID 29155147, PMID 33707534, PMID 35013352, PMID 39161060). One 2018 study reported that its NNMT inhibitor produced no observable adverse effects in mice — a mouse observation, not a human safety finding. Any article quoting side-effect percentages for 5-Amino-1MQ is citing something the research does not contain. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience: Zero Monitored Humans

For our cagrilintide and eloralintide side-effect pages, this box summarizes what thousands of monitored trial participants actually went through. For 5-Amino-1MQ, the honest version is different: no human being has ever taken 5-Amino-1MQ under study conditions where side effects were recorded. The closest thing to a documented experience is a mouse on a high-fat diet, weighed and dissected on a fixed schedule.

People do buy 5-Amino-1MQ — it moves steadily in the research-chemical market as a weight-loss “biohacker” compound. Those experiences exist; they have simply never been collected, controlled, or published. That is not a footnote. It is the entire human safety picture, and it is blank.

When we publish an individual account here, it will be a real person, named with permission — like the reader experiences we reference in our visceral fat-loss guide. We don’t write fiction into this slot.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is 5-Amino-1MQ?

5-Amino-1MQ is 5-amino-1-methylquinolinium — a small molecule, not a peptide, despite being sold beside peptides in the research-chemical market. It inhibits nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme with newly identified roles in cellular metabolism and energy homeostasis (PMID 29155147). Its entire claim to relevance rests on studies in obese mice showing that blocking NNMT reduces body weight and fat mass. It has no amino-acid backbone, and is often filed next to the SLU-PP-915 “exercise mimetic” as a metabolic small molecule with a big preclinical story and no clinical file at all. This page covers the safety question — which, for 5-Amino-1MQ, means covering an absence honestly.

How It’s Thought to Work

NNMT takes nicotinamide (a form of vitamin B3) and methylates it, consuming a methyl group from SAM and producing 1-MNA (1-methylnicotinamide). Inhibit the enzyme and, in cultured adipocytes, several things move together: intracellular 1-MNA falls, intracellular NAD+ rises, SAM rises, and lipogenesis — the cell’s fat-building program — is suppressed (PMID 29155147). The proposed logic is that NNMT sits at a junction of two fundamental currencies — the NAD+ pool that powers metabolism and the methylation supply that regulates gene expression — and that freeing those up shifts fat cells away from storage. Mechanistic plausibility is real. But note what a mechanism is not: it is not a safety profile. A compound that reroutes NAD+ and methylation traffic across every cell type can, by the same token, do things nobody ordered — and none of that has been checked in a person.

KEY TAKEAWAY

5-Amino-1MQ has a coherent mechanism — NNMT inhibition that raises NAD+ and SAM while suppressing fat storage in adipocytes — and a stack of supportive mouse studies. That is the complete file. Every side-effect rate you have seen attached to this compound was generated somewhere other than 5-Amino-1MQ research on humans, because that research does not exist.

The Entire Evidence Base: Four Rodent-and-Cell Studies

The literature worth knowing in full, because it is all of it. The founding paper (PMID 29155147, Biochem Pharmacol, 2018) validated NNMT as an anti-obesity target: it profiled a series of membrane-permeable methylquinolinium inhibitors, showed they were selective — not inhibiting related SAM-dependent methyltransferases or the NAD+ salvage enzymes — and reported that a potent one, given systemically to obese mice, significantly reduced body weight and white adipose mass, decreased adipocyte size, and lowered plasma total cholesterol.

Three follow-ups built on that. A 2021 study (PMID 33707534, Sci Rep) combined NNMT inhibition with a reduced-calorie diet in obese mice and reported accelerated fat loss, reduced liver and white-adipose weights, improved hepatic steatosis, and body composition normalized to lean controls. A 2022 study (PMID 35013352, Sci Rep) named the compound explicitly and found a distinct cecal microbiome signature (decreased Erysipelatoclostridium, increased Lactobacillus) in treated mice. The most detailed is 2024 (PMID 39161060, Diabetes Obes Metab), which dosed obese mice with 5A1MQ once daily for 28 days and added pharmacokinetics. Four papers, all mice or cells, none human. Set that beside cagrilintide, which carries placebo-controlled adverse-event tables from thousands of participants, and “evidence base” reveals itself as a spectrum, not a checkbox.

The Human Side-Effect Dataset That Doesn’t Exist

A real side-effect profile requires four things: humans receiving the compound, a control group, systematic recording of everything that happens, and publication. 5-Amino-1MQ has none of the four. There is no adverse-event table for it anywhere in the human literature, because there is no human study. “No data” is literal here, and it cuts both ways: nothing proves harm, and nothing demonstrates safety in people — the same absence we mapped for the copper peptide AHK-Cu, another compound sold on a reputation its studies never built.

PERSONAL OBSERVATION — PI EDITORIAL

Reading the four studies side by side, what struck us is how quickly a mouse abstract’s caution gets laundered into human confidence downstream. The 2018 paper’s careful line — no observable adverse effects in the treated mice — reappears across seller pages as “well tolerated,” full stop, species deleted. Watching one hedged rodent sentence shed its qualifiers on the way to a product description was the clearest lesson this compound had to offer: the confidence of a claim and the population it was measured in are two entirely separate facts.

What “No Observable Adverse Effects” Meant in the Mice

The most-quoted safety line for 5-Amino-1MQ comes from the 2018 paper, which reported that its NNMT inhibitor did not impact total food intake nor produce any observable adverse effects in the diet-induced obese mice (PMID 29155147). Read it precisely: “no observable adverse effects” describes what researchers saw in one mouse experiment over the study window — not a systematic toxicology screen, not a human tolerability finding, not a statement about long-term exposure. The 2024 study points the same way, with normalized circulating alanine transaminase, aspartate transaminase, and ketone bodies and improved liver histology in treated mice (PMID 39161060) — encouraging for the liver, still entirely murine. None of it converts into a human side-effect rate. It is a favorable rodent signal, labeled as exactly that.

The NAD+ and Methylation Question

Here is the part that deserves more caution than the sales copy gives it. 5-Amino-1MQ does not act on a niche fat-tissue pathway in isolation; it raises intracellular NAD+ and SAM by blocking an enzyme that touches two of the cell’s most fundamental systems (PMID 29155147). NAD+ is the currency of energy metabolism; SAM is the universal methyl donor that regulates gene expression across every tissue. Nudging both at once is why the mechanism is interesting — and why “it just helps fat cells” undersells what a systemic NNMT inhibitor is doing. What a sustained shift in methylation supply does over years, in organs the mouse work did not follow, in a human, is uncharacterized. We flag the biology because it is real and cited; we won’t extend it into toxicity claims or safety guarantees the literature doesn’t contain. For broader context, our NAD+ hub covers what is and isn’t established.

Routes: What the Mouse PK Study Actually Used

Unlike most compounds in this market, 5-Amino-1MQ was designed to be membrane-permeable, and the 2024 study characterized its pharmacokinetics after three routes in mice: intravenous, oral, and subcutaneous dosing (PMID 39161060). It reported high systemic exposure and effective distribution to metabolically active tissues — adipose, muscle, and liver — after subcutaneous dosing. Research-market products appear as both capsules and lyophilized powder, which tracks with an orally-permeable small molecule. None of that establishes a human route recommendation: mouse PK is not human PK, and no absorption or safety data for any route exists in people.

PRACTICAL NOTES — HANDLING A RESEARCH SMALL MOLECULE

  • The mouse PK study used intravenous, oral, and subcutaneous routes — none of which is a human dosing recommendation
  • A batch-matched COA is the only evidence a vial or capsule contains 5-amino-1-methylquinolinium at the stated quantity
  • Reconstitution arithmetic for any powdered research compound is on the buyer — our peptide calculator does the math and deliberately nothing else
  • Everything in this channel is sold strictly for non-human research use

Why “No Reported Side Effects” Isn’t “No Side Effects”

The most common safety sentence written about 5-Amino-1MQ — “no side effects have been reported” — is technically true and structurally empty. Reporting requires a mechanism: trials with adverse-event logging, a pharmacovigilance system, published case reports. As an unapproved compound sold outside medicine, 5-Amino-1MQ has none of them. A user who felt off after a few weeks tells a forum or nobody; neither shows up in a literature search. Absence of evidence here reflects absence of surveillance, not surveillance returning a clean result. The identical sentence would be equally “true” of any compound nobody has studied in humans — which is exactly why it means so little.

What Users Report: Self-Reported Effects From Reddit

Every safety statement on this page comes from mice, so the only descriptions of what 5-Amino-1MQ does to a person are self-reports. We searched Reddit on September 5, 2026, found 57 relevant posts from 2025 to 2026, and read the comment threads of nine, across r/BodyHackGuide, r/PeptideGuide, r/Retatrutide, r/Peptides, r/Biohacking, r/BiohackingU and r/powerbuilding. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified. Almost nobody takes it alone: nearly every poster also uses a GLP-1 agonist, testosterone or a SARM, SLU-PP-332, MOTS-c or injected NAD+, and the most-upvoted thread is a physique photo credited to S4 and 5-Amino, no effects described, replies assuming testosterone (r/powerbuilding).

The effect people report is energy, mostly measured against GLP-1 fatigue. More than two dozen distinct posters describe a stimulant-free lift they call “clean energy”. The most-read account, a cycle review cross-posted to two subreddits, pairs 5-Amino with retatrutide; the poster felt nothing at 300 micrograms, felt it at 5 mg a day, and cannot say which compound moved the fat (r/BodyHackGuide, r/Retatrutide). The most-upvoted reply credits it with erasing tirzepatide fatigue, alongside NAD+ and a free vendor vial. A contest-prep competitor live-blogged doses from 5 mg injected to 150 mg tablets and back to 1 to 2 mg, reporting energy throughout (thread). One retatrutide user with results still called it overkill, since coffee gave the same lift (thread).

At least ten posters felt nothing across the whole dose range. One ran 5 mg injected daily for six weeks and noticed nothing (thread); another, eleven weeks into 1 mg a day, could not tell; two retatrutide users on 50 and 100 mg by mouth got no relief (thread). A poster who followed SS-31 with a month of 5-Amino, MOTS-c and NAD+ felt nothing; a very lean poster got zero energy, zero fat loss and odd stool from the orange powder; a third on 2 mg a day called any effect probably placebo (r/BiohackingU). A longevity-stack poster on tirzepatide and testosterone said two weeks was too early to judge 5-Amino (r/Biohacking).

Doses disagree by three orders of magnitude, and the injection-site reports come from people who guessed high. The guide’s author put the injectable dose at 150 micrograms; the argument beneath pits posters calling micrograms placebo and 20 to 50 mg effective against posters calling 5 mg a day reckless, all citing unsourced bioavailability figures (thread). One poster there injected 25 mg twice and 10 mg five times and, with subdermal nodules still healing, took two weeks off. A retatrutide user’s belly injections welted and burned until moved to the upper glute (thread). A night-shift worker described about 84 mg a day, home-mixed from raw powder, with about 80 mg of SLU-PP-332 and 15 mg a week of retatrutide, and nine kilograms lost in two weeks; commenters called both the rate and the retatrutide dose alarming (r/Peptides).

The recurring negatives are sleep, a crash on stopping and diarrhea. A poster who escalated to 80 mg a day was not tired until seventeen hours awake and was cutting back (thread); a 2 mg user who otherwise felt nothing said night doses kept them awake (thread); three others said sleep was untouched. At least three described the first days off as a crash in the gym (r/Retatrutide, r/BodyHackGuide, r/BiohackingU). One oral user got bad diarrhea on 35 mg tablets twice a day but could not separate it from retatrutide’s. The only bloodwork in nine threads is the competitor’s post-show panel, liver and kidney markers slightly elevated and attributed to prep (thread). Nobody reported a heart-rate change; the one poster who asked got no answer.

HOW TO READ SELF-REPORTS

Nine threads yield one consistent claim, more daytime energy, against GLP-1 fatigue, NAD+, SARMs and SLU-PP-332 that no poster could subtract out. The mouse studies above never measured energy, sleep or gut effects, so these anecdotes neither confirm nor contradict them. With doses spanning a thousand-fold and at least ten null reports, neither frequency nor causation can be read here; the nodules, diarrhea and insomnia are single accounts about products nobody assayed.

Doses: What the Mouse Studies Administered

This is where honest coverage has to disappoint. The abstracts describe the mouse dosing only in general terms: the 2024 study gave 5A1MQ once daily for 28 days and reported that it “dose-dependently” limited body weight and fat mass gains (PMID 39161060), while the earlier papers describe “systemic” administration of a “potent” inhibitor without a figure in the abstract. What they do not give is the milligram-per-kilogram dose — the one number a person would need to attempt any translation. No human-equivalent dose can be responsibly derived from “dose-dependent in mice,” and we won’t invent one. Any product label suggesting a specific human dose is not reading it off the science.

DID YOU KNOW

The longest 5-Amino-1MQ dosing window in the published record is 28 days — in mice (PMID 39161060). There is no published human study of any duration, which means the question people most want answered — what happens over months — has never been tested in our species at all.

Stacking 5-Amino-1MQ: GLP-1s, NAD Boosters, and the Missing Studies

The combinations people actually run — 5-Amino-1MQ alongside a GLP-1 agonist for weight loss, or paired with NAD+ precursors on the theory that both raise NAD+ — have no published studies as combinations, in any species. The NAD+ pairing especially: 5-Amino-1MQ’s benefit already runs partly through raising NAD+, so combining it with a dedicated NAD+ product stacks two interventions aimed at overlapping biology with zero data on the sum — not a prediction of harm, an observation that the uncertainty compounds rather than cancels. The adjacent, better-studied metabolic evidence lives on our visceral fat-loss guide and peptides-for-energy overview.

How This Compares to Compounds With Real Safety Data

It is worth being blunt about the gap. When we write up eloralintide or cagrilintide, we can quote nausea rates against a placebo column from human trials. For 5-Amino-1MQ there is no active-arm rate and no placebo column, because there is no human arm — only vehicle-versus-treatment comparisons in mice. A “no adverse effects” line in mice and a human trial’s adverse-event rate are not two points on one scale; they come from different species measured in different ways. More unknowns is the only defensible way to describe the comparison. The small molecule closest to it in this batch, SLU-PP-915, sits in the identical position — a strong rodent story and an empty human page.

Where Lab Data Stops: The Research-Product Reality

With a trial-backed drug, the research-vial problem is that the vial doesn’t inherit the trials. With 5-Amino-1MQ it is starker: there are no human trials to inherit, so the product rests entirely on its own documentation. The gap shows up three ways: identity and purity (a batch-matched COA is the only evidence the product contains 5-amino-1-methylquinolinium at the stated quantity), dose arithmetic (the math per capsule, or reconstitution with bacteriostatic water, is on the buyer), and no reference point — there is no “trial-grade experience” to compare against, because none was run. Everything in this channel is sold strictly for non-human research use.

PERSONAL OBSERVATION — PI EDITORIAL

In listings we’ve reviewed, the pattern is consistent: 5-Amino-1MQ is sold with the vocabulary of a finished weight-loss drug — “clinically studied,” tidy dosing charts — riding on four papers that never left the mouse room. We keep a simple rule for pages like this one: count the human studies before trusting the human-facing adjectives. Here the count is zero, and every dosing chart in the sales copy is doing work the science never did.

Sourcing and Verification

For a compound with no human safety literature, product quality is the only safety variable you can actually influence. The checklist doesn’t change: a batch-matched COA naming the compound and quantity, independent third-party testing with a verifiable report number, and skepticism toward any listing that pairs “clinically proven” language with a set of mouse studies. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews show what passing documentation looks like, and our guide library covers verification in depth.

US Regulatory Status

5-Amino-1MQ is not an approved drug and has never been evaluated by the FDA for any purpose. It exists in a single channel: the research-chemical market, where it is sold for non-human research use with no regulatory review of identity, purity, or safety. There is no prescription or over-the-counter version. NNMT inhibition is a legitimate area of academic and early commercial interest, but as of this writing we can find no registered human clinical program for 5-amino-1-methylquinolinium specifically — so, unlike an investigational drug in trials, there is no scheduled human readout on the horizon to fill this page’s gaps. When that changes, this section changes with it.

Frequently Asked Questions

What are the side effects of 5-Amino-1MQ?

Unknown in humans — literally. No human study of 5-Amino-1MQ has ever been published, so no human side-effect rates exist. The four published studies are in obese mice and cultured cells. One 2018 paper reported no observable adverse effects in the treated mice, which is a rodent observation, not a human safety finding.

Is 5-Amino-1MQ safe?

No published human data answers that in either direction. Nothing documents harm in people; nothing demonstrates safety in people — the compound has never been through a human study capable of measuring either. Its reputation rests on favorable results in mice, which do not transfer directly to humans.

Is 5-Amino-1MQ a peptide?

No. Despite being sold in the peptide research market, 5-Amino-1MQ is a small molecule — 5-amino-1-methylquinolinium — that inhibits the enzyme NNMT. It has no amino-acid backbone and works by a different mechanism than the peptides beside it on vendor menus.

How does 5-Amino-1MQ work?

It inhibits nicotinamide N-methyltransferase (NNMT). In cultured fat cells, blocking NNMT lowered the reaction product 1-MNA, raised intracellular NAD+ and SAM, and suppressed lipogenesis; in obese mice it reduced body weight and fat mass. All of that is preclinical, and unmeasured for safety in humans.

What dose of 5-Amino-1MQ did the studies use?

The abstracts describe dosing only in general terms — once daily for 28 days, dose-dependent, systemic — without the milligram-per-kilogram dose given to the mice. No human dose has ever been established, and a mouse dose would not convert directly to a human one. This page does not provide dosing advice.

How is 5-Amino-1MQ different from a drug like semaglutide?

Entirely different mechanism, and entirely different evidence level. Approved weight-loss drugs have large human trials with adverse-event tables and a placebo comparison. 5-Amino-1MQ has four preclinical papers in mice and cells and no human trial at all, so the two cannot be compared on safety.

Glossary of Terms

  • 5-Amino-1MQ: 5-amino-1-methylquinolinium, a small-molecule inhibitor of the enzyme NNMT, marketed for fat loss in the research-chemical market.
  • NNMT: nicotinamide N-methyltransferase, a cytosolic enzyme that methylates nicotinamide; the target 5-Amino-1MQ blocks.
  • NAD+: nicotinamide adenine dinucleotide, a central energy-metabolism cofactor; intracellular NAD+ rose when NNMT was inhibited in adipocytes.
  • SAM: S-adenosylmethionine, the universal methyl donor for gene regulation; also rose with NNMT inhibition in the cell studies.
  • 1-MNA: 1-methylnicotinamide, the product NNMT generates; its intracellular level fell when the enzyme was inhibited.
  • Diet-induced obese (DIO) mice: mice made obese on a high-fat diet, the model used in every published 5-Amino-1MQ efficacy study.
  • COA (certificate of analysis): the lab document identifying a research product’s contents; batch-matched or it proves nothing.

References